TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33843789
Drug: Intravenous estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous estrogen (25 mg)
Study: 36356632
Drug: aprocitentan 12·5
Approvals — FDA: no, EMA: no, PMDA: no
Description: aprocitentan 12·5 mg
Study: 35686330
Drug: aprocitentan 25
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: aprocitentan 25 mg
Study: 33470031
Drug: 1.1 GBq
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1 GBq radioiodine therapy
Study: 33470031
Drug: 3.7 GBq
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.7 GBq radioiodine therapy
Study: 35927733
Drug: Weekly saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly saline (0.9%) washout in addition to standard LTC care
Study: 35927733
Drug: Weekly citric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly citric acid (3.23%) washout in addition to standard LTC care
Study: 34806783
Drug: Galcanezumab 300
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Galcanezumab 300 mg monthly for 12 weeks
Study: 36145083
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of arginine and leucine supplementation and supervised adapted physical activity program (ALs+APA group, n = 20)
Study: 33245150
Drug: Time Out
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Time Out consultation (TOC) before treatment decision
Study: 32144927
Drug: Contralateral needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contralateral needling therapy
Study: 35063278
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (200 mg daily alternating weeks) and Tamoxifen (20 mg twice daily)
Study: 36241853
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg CBD
Study: 35637624
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg CBD
Study: 33021455
Drug: Flumazenil (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.05 mg/kg SC)
Study: 34530886
Drug: Four-factor prothrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-factor prothrombin complex concentrate (PCC) 1 mL/kg (25 IU/ml of Factor IX/Kg) within 1-h post-admission
Study: 34530886
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution 0.9% as a placebo
Study: 33934982
Drug: Conventional oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oxygen therapy through a simple oxygen mask
Study: 32560744
Drug: Candidate agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candidate agents for COVID-19 treatment (specific candidates not detailed)
Study: 35015750
Drug: Manual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual treatment maneuvers
Study: 33181655
Drug: Comprehensive geriatric
Normalized name: CATHETER,EXTERNAL CONVEEN #5120 GERIATRIC/PEDIATRIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive geriatric assessment (CGA) and multi-disciplinary management including rehabilitation exercise, diet adjustment, multi-drug evaluation, acupoint massage in TCM, and patient education for 12 months
Study: 35272599
Drug: COVID‐19 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID‐19 vaccine (CoronaVac)
Study: 32585226
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration (10 L/min by face mask)
Study: 35770251
Drug: QazCovid-in® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: QazCovid-in® vaccine (5 μg each, 2 doses, 21 days apart)
Study: 35770251
Drug: QazCovid-in® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: QazCovid-in® vaccine
Study: 32386922
Drug: First drug
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First drug administration
Study: 34759559
Drug: Intraperitoneal nebulization
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal nebulization with 4 ml of 0.75% ropivacaine (Group B)
Study: 34759559
Drug: Intraperitoneal nebulization
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal nebulization with 4 ml of saline (Group C)
Study: 36333692
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (5000 units weekly for 3 months)
Study: 33998243
Drug: Sacubitril/valsartan (S/V)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (S/V) treatment
Study: 36106548
Drug: Restricted sacubitril/valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted sacubitril/valsartan (rS/V) treatment
Study: 36106548
Drug: Conventional HF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional HF treatment (non-S/V)
Study: 32976864
Drug: L-GrAFT7 risk
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-GrAFT7 risk score
Study: 32976864
Drug: L-GrAFT7 risk
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-GrAFT7 risk score (highest tertile)
Study: 32221696
Drug: NIC 18.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIC 18.7 mg/g
Study: 32221696
Drug: NIC 10.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIC 10.8 mg/g
Study: 32221696
Drug: NIC 5.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIC 5.3 mg/g
Study: 32221696
Drug: NIC 2.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIC 2.3 mg/g
Study: 32221696
Drug: NIC 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIC 1.3 mg/g
Study: 32221696
Drug: NIC ≤
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NIC ≤ 2.3 mg/g
Study: 32221696
Drug: NIC ≥
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NIC ≥ 5.3 mg/g
Study: 35147131
Drug: Tripterygium wilfordii
Normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium wilfordii multiglycosides tablets (1-1.5 mg/kg body weight/d, orally) in addition to angiotensin converting enzyme inhibitor/angiotensin receptor blocker
Study: 35147131
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitor/angiotensin receptor blocker
Study: 33328115
Drug: Gabby intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabby intervention (online conversational agent)
Study: 32171422
Drug: Rifampicin 10
Normalized name: Rifampicine
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 10 mg/kg plus clarithromycin 15 mg/kg extended release once daily for 8 weeks (RC8)
Study: 32171422
Drug: Rifampicin 10
Normalized name: Rifampicine
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 10 mg/kg plus intramuscular streptomycin 15 mg/kg once daily for 8 weeks (RS8)
Study: 35324230
Drug: Web‐PE (Web‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web‐PE (Web‐based Prolonged Exposure Therapy)
Study: 35324230
Drug: PCT (Present‐Centered
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT (Present‐Centered Therapy)
Study: 33121439
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence monitoring and quality of life assessments using validated self-reported instruments (EQ-5D-5L)
Study: 36482599
Drug: Sublingual Immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual Immunotherapy with Dermatophagoides Farinae Drops for 3 months
Study: 36482599
Drug: Mometasone Furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone Furoate nasal spray for 3 months
Study: 36482599
Drug: Sublingual Immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual Immunotherapy
Study: 36482599
Drug: Mometasone Furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone Furoate nasal spray
Study: 34340637
Drug: Sequential combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combination of aerobic exercise and computerized cognitive training (n = 20)
Study: 35397826
Drug: Single session
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single session treatment
Study: 35397826
Drug: Weekly treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly treatment
Study: 33894838
Drug: Cagrilintide 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cagrilintide 1.2 mg with semaglutide 2.4 mg
Study: 33894838
Drug: Cagrilintide 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cagrilintide 2.4 mg with semaglutide 2.4 mg
Study: 33894838
Drug: Cagrilintide 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cagrilintide 4.5 mg with semaglutide 2.4 mg
Study: 33894838
Drug: Cagrilintide (0.16–4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cagrilintide (0.16–4.5 mg) and semaglutide 2.4 mg
Study: 34353065
Drug: Floating needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floating needle therapy combined with acupoint embedding
Study: 32685097
Drug: Mulberry milk
Normalized name: MULBERRY
DrugBank: Broussonetia papyrifera pollen (DB10736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mulberry milk (10 g)
Study: 32685097
Drug: Placebo milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo milk (50 mL)
Study: 35191639
Drug: Bilateral lumbar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral lumbar ultrasound-guided erector spinae plane block (ESPB) with 0.375% ropivacaine 40 mL
Study: 35191639
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration with 0.375% ropivacaine 40 mL
Study: 33710764
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy (combination therapy group)
Study: 33710764
Drug: Pembrolizumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab monotherapy (monotherapy group)
Study: 33710764
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with PD-L1 TPS ≥50% in combination therapy group
Study: 33710764
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with PD-L1 TPS ≥50% in monotherapy group
Study: 36148625
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) powder
Study: 33762145
Drug: High-dose coaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose coaching with ECHO
Study: 33762145
Drug: High-dose coaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose coaching without ECHO
Study: 33762145
Drug: Low-dose coaching
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose coaching with ECHO
Study: 33762145
Drug: Low-dose coaching
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose coaching without ECHO
Study: 33557035
Drug: CE+HCO3 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE+HCO3 group (carbohydrate-electrolyte solution with bicarbonate)
Study: 35455245
Drug: MF59-adjuvanted, H5N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted, H5N1 influenza pandemic vaccine (aH5N1c), two doses administered 21 days apart
Study: 35455245
Drug: MF59-adjuvanted, H5N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted, H5N1 influenza pandemic vaccine (aH5N1c)
Study: 36158118
Drug: Improved oral
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved oral care method (oral scrubbing before intubation, brushing and washing after intubation, 3 times per day, using 0.1% povidone-iodine in oral care solution)
Study: 36158118
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral care (scrubbing 3 times per day, using physiological brine)
Study: 36158118
Drug: Improved oral
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved oral care method
Study: 33732655
Drug: Maternal antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal antibiotic usage
Study: 36052499
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and common medication
Study: 36052499
Drug: Common medication
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common medication only
Study: 32338445
Drug: HOPE service
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOPE service (brief psychological therapy)
Study: 33277507
Drug: tiotropium/olodaterol (5/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiotropium/olodaterol (5/5 µg) via Respimat® inhaler
Study: 35189093
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg vaginal progesterone suppository nightly from 16 to 36 weeks of gestation
Study: 35189093
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg intramuscular 17-hydroxyprogesterone caproate weekly from 16 to 36 weeks of gestation
Study: 35189093
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg vaginal progesterone suppository nightly
Study: 35189093
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg intramuscular 17-hydroxyprogesterone caproate weekly
Study: 32701012
Drug: OBG 8
Normalized name: OBGYN Procedure Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBG 8 times daily for 3 days, followed by 4 times daily for 11 days (Group 1)
Study: 32701012
Drug: OBG 4
Normalized name: OBGYN Procedure Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBG 4 times daily for 14 days (Group 2)
Study: 35257461
Drug: iGlarLixi (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: iGlarLixi (insulin glargine 100 U/ml + lixisenatide)
Study: 94240848
Drug: Sclerotherapy in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerotherapy in combination with enalapril
Study: 36222207
Drug: Bromocriptine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (7.5 mg daily) in group 1 (early-onset androgenic alopecia)
Study: 36222207
Drug: Bromocriptine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (7.5 mg daily) in group 2 (normal hair growth)
Study: 34338111
Drug: Non-selective beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective beta-blockers (n = 113)
Study: 34338111
Drug: Non-selective beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective beta-blockers (n = 40)
Study: 34338111
Drug: Selective beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective beta-blockers and metformin
Study: 33164945
Drug: 24-hour infusion
Normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour infusion of levodopa/carbidopa (720/90 mg)
Study: 33164945
Drug: 14-hour 'waking-day'
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-hour 'waking-day' infusion of levodopa/carbidopa (538/68 mg plus a morning oral dose of 150/15 mg)
Study: 32451212
Drug: Trivalent live
Normalized name: influenza vaccine trivalent live 2024-2025 (2 yrs-49 yrs) 10exp6.5-7.5 FF unit/0.2 mL NASAL NASAL SPRAY SYRINGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent live human-lamb reassortant rotavirus vaccine (LLR3)
Study: 35151280
Drug: Mictalase® suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mictalase® suppositories (Phenolmicin P3 and Bosexil) administered twice a day for 5 days, then once a day for 10 days
Study: 35507481
Drug: ZF2001 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZF2001 vaccine (25-μg doses, 3 doses, 30 days apart)
Study: 35604960
Drug: Topical 10
Normalized name: urea topical 10% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 10 mg Z-endoxifen
Study: 35604960
Drug: Topical 20
Normalized name: urea topical 20% topical foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 20 mg Z-endoxifen
Study: 33993571
Drug: alfentanil 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 14 mcg kg−1
Study: 33993571
Drug: rocuronium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.3 mg kg−1
Study: 33993571
Drug: propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol 2 mg kg−1
Study: 34655071
Drug: Intracavernosal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal injection of autologous mesenchymal stem cells (50-60 ×106 cells)
Study: 34655071
Drug: Intracavernosal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernosal injection of autologous mesenchymal stem cells
Study: 36421007
Drug: Immunotherapy added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immunotherapy added to chemotherapy
Study: 33407345
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy at the most pain-sensitive segment
Study: 33407345
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy at the stiffest segment
Study: 32379165
Drug: Topical almond
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical almond oil (6.5 cc applied daily for 7 days)
Study: 32379165
Drug: Placebo (liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (liquid paraffin, 6.5 cc applied daily for 7 days)
Study: 32379165
Drug: Topical almond
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical almond oil
Study: 32319999
Drug: NT‐proBNP‐guided treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT‐proBNP‐guided treatment (goal to suppress NT‐proBNP concentrations to <1000 pg/mL)
Study: 32319999
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of β‐blockers
Study: 32319999
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of ACE inhibitors
Study: 32319999
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of ARBs
Study: 32319999
Drug: Increasing doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of mineralocorticoid antagonists
Study: 35947884
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo treatment for three weeks
Study: 35947884
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no open-label placebo treatment)
Study: 33788987
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events from LED-RL treatment
Study: 34151132
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of adjuvant afatinib (30 mg by mouth daily)
Study: 34151132
Drug: 2 years
Normalized name: Childrens Panadol 5 - 12 Years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 years of adjuvant afatinib (30 mg by mouth daily)
Study: 34156697
Drug: Olfactory rehabilitation
Normalized name: BOS TAURUS OLFACTORY BULB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olfactory rehabilitation plus daily oral supplement with Palmitoylethanolamide (PEA) and Luteolin
Study: 35850742
Drug: Daily Contact
Normalized name: CONTACT LENS DAILY CLEANER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Contact Testing (DCT) using Lateral Flow Test (LFT) and two Polymerase Chain Reaction (PCR) tests for 7 days
Study: 33127945
Drug: 75/650 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75/650 mg tramadol with paracetamol every 8 hours
Study: 33127945
Drug: 37.5/325 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5/325 mg tramadol with paracetamol every 8 hours
Study: 34156898
Drug: Romyelocel-L infusion
Normalized name: Romyelocel-L
DrugBank: Romyelocel-L (DB19268)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romyelocel-L infusion on d9 with granulocyte colony-stimulating factor (G-CSF) starting daily d14
Study: 34156898
Drug: G-CSF daily
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF daily alone on d14 (control)
Study: 34459905
Drug: Mobile app
Normalized name: Mahana IBS CBT Mobile Application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile app for pediatric drug preparation (n = 74)
Study: 34459905
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug preparation methods (n = 76)
Study: 36942789
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone
Study: 34233965
Drug: Nangibotide (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nangibotide (two doses)
Study: 33460048
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate
Study: 34614447
Drug: SEP‐4199 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP‐4199 200 mg/d
Study: 34614447
Drug: SEP‐4199 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP‐4199 400 mg/d
Study: 32270926
Drug: Fenebrutinib 200
Normalized name: Fenebrutinib
DrugBank: Fenebrutinib (DB14785)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenebrutinib 200 mg twice daily